Marvel Biosciences Corp. (MRVL.V)
| Previous Close | 0.0950 |
| Open | 0.1000 |
| Bid | 0.0950 x N/A |
| Ask | 0.1000 x N/A |
| Day's Range | 0.0950 - 0.1000 |
| 52 Week Range | 0.0850 - 0.3900 |
| Volume | |
| Avg. Volume | 13,317 |
| Market Cap | 3.096M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Marvel Biosciences Announces Non-Brokered Private Placement
Calgary, Alberta--(Newsfile Corp. - June 21, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a proposed non-brokered private placement of units (the "Units") at a price of $0.10 per Unit for gross proceeds of up to $700,000 (the "Offering"). Each Unit will be comprised of one common share in the capital of the Company (a "Common Share") and ...
- Newsfile
Marvel Biosciences Initiates Formulation Development with Catalent
Calgary, Alberta--(Newsfile Corp. - April 6, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that has initiated its pre-clinical oral formulation studies for its lead compound MB-204 with Catalent, Inc.Catalent, one of the world's largest contract research organizations, has begun development of novel solid ...
- Newsfile
Marvel Biosciences Announces Second Quarter 2022 Financial Results
Calgary, Alberta--(Newsfile Corp. - March 30, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel") today announced its financial results for the second quarter ended January 31, 2022. For further information on these results, please see the Marvel Biosciences Corp. Condensed Interim Consolidated Financial Statements and Management Discussion & Analysis as filed on SEDAR."During the quarter ended January
